Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

ConferencePositive

AI Analysis

Summary

Biogen presented supportive anti-tau data for Alzheimer's disease at AAIC, while Compass Pathways advanced psychedelics with positive data and FDA guidance. AstraZeneca and Ionis' late-stage antisense therapeutic for ATTR-CM failed, creating a market shift in the cardiac amyloidosis space.

Outcome Details

Biogen presented positive anti-tau data; Compass Pathways reported positive psychedelics data with FDA final guidance; AstraZeneca/Ionis antisense therapeutic for ATTR-CM failed in late-stage development

Importance:7/10

Sentiment:

0.30

Alzheimer's diseasetau pathologypsychedelicsATTR-CMantisenseAAIC conferencelate-stage failure

Related Companies

$BIIB $CMPS $AZN $IONS

Read the original article

Published by BioSpace on July 15, 2026 12:57 PM

Read Original